Building Commercial Conviction Before Launch: Interview with SetPoint Medical CEO Murthy Simhambhatla

In this episode, we sat down with we sat down with Murthy Simhambhatla, CEO of SetPoint Medical. SetPoint is commercializing the first FDA-approved neuroimmune modulation implant for rheumatoid arthritis. Previously, Murthy was CEO of Evolus, leading the company through its IPO, and held multiple leadership roles at Abbott, including President of Abbott Medical Optics and head of the company's Ibis Biosciences molecular diagnostics business. Earlier in his career, Murthy led development of Abbott's XIENCE drug-eluting stent platform following Abbott's acquisition of Guidant. Murthy holds a Ph.D. in Polymer Engineering and is a Fellow of the American Institute for Medical and Biological Engineering. In this interview, Murthy discusses building commercial conviction years before launch, how to sequence platform indications around adjacent markets, and why SetPoint built its reimbursement function in-house rather than outsourcing it.